Abstract: The present study aimed at synthesizing the process related potential impurities of aceclofenac. Aceclofenac is an orally administered phenyl acetic acid derivative with effects on a variety of inflammatory mediators. oxy] acetate (benzyl ester of aceclofenac) was synthesized by condensation of diclofenac sodium with benzylbromoacetate. Impurity I:1-(2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one was synthesized by acid cyclization of diclofenac. The present study has provided an efficient method for synthesis of process related aceclofenac impurities.
Introduction
Aceclofenac is an orally administered phenyl acetic acid derivative with effects on a variety of inflammatory mediators. Aceclofenac is chemically 2-[[2-[2-[(2, 6-dichlorophenyl)amino] phenyl]acetyl]oxy]acetic acid 1 . Aceclofenac has been shown to have potent analgesic and antiinflammatory activities, similar to indomethacin and diclofenac and due to its preferential cyclooxygenase-2 (COX-2) blockade, it has better safety than conventional non-steroidal antiinflammatory drugs (NSAIDs) with respect to adverse effects on gastrointestinal and cardiovascular system. It is indicated for long term management of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. It is also widely used in condition of mild to moderate pain and post-operative pain, dysmenorrhoea, musculoskeletal trauma and gonalgia.
RESEARCH ARTICLE
Impurity is any component of a drug substance (excluding water) that is a chemical entity other than the active pharmaceutical ingredient 2 . According to 'International Conference on the Harmonisation (ICH) guidelines impurities can be broadly classified into three categories for the drug substance produced by chemical synthesis 3, 4 .
• Organic impurities -stating material, process related products, intermediates and degradation products.
• Inorganic impurities -salts, catalyst, ligands and heavy metals or other residual metals.
• Residual solvents -organic and inorganic liquids used during production or crystallization.
The presence of impurities on pharmaceuticals can have significant effect on their quality and their safety. The safety of a drug is determined by its pharmacological-/toxicological profile as well as the adverse effects caused by the impurities in bulk and dosage forms. The impurities in drugs often possess unwanted pharmacological or toxicological effects by which any benefit from their administration may be outweighed. Therefore, it is quite obvious that the products intended for human consumption must be characterized as completely as possible 5 .
The quality and safety of a drug is generally assured by monitoring and controlling the impurities effectively. Hence testing for impurities and their evaluation have been important elements of the International Conference of Harmonization (ICH) process 6 . A description of the identified and unidentified impurities present in new drug substance is known as impurity profile. Regulatory requirements for the identification, quantification and control of impurities in drug substances and their formulated products are now being increasingly explicitly defined, particularly through the International Conference of Harmonization.
The most critical aspect of the elaboration of the guidelines was the definition of the levels of impurities for identification and qualification. Qualification is the process of acquiring and evaluating data for establishing the biological safety of an individual impurity or a given impurity profile at the levels specified. The level of any impurity present in a new drug substance that has been adequately tested in safety and clinical studies is considered qualified.
Chemistry and safety aspects of impurities are a central focus of this quality concept during the development stages. In the early drug development stages, the level of impurities is usually higher, experience and information are limited, and there is greater variability in the synthetic process, particularly during optimization and scale up 7 . Another important role of the synthesized impurities is its use as an impurity standard in the course of final step of impurity profiling, when selective, quantitative method is developed for determining the impurity 8 . Keeping in view the stringent purity requirements from the regulatory authorities that the impurities ≥ 0.1% must be identified and characterized. This present work describes synthesis of process related impurities of aceclofenac listed in British Pharmacopoiea 9 (BP) and characterization of synthesized impurities by FT-IR, MS and 1 H NMR data
Experimental
Melting points were determined in open capillary tubes on a Thermonik melting point apparatus and were found uncorrected. Infra red spectra were recorded on Fourier Transform IR spectrophotometer (Shimadzu FT-IR 8700) using KBR ( ν max in cm -1 ) disc method. 1 H NMR spectra were recorded in CDCl 3 on Brucker 200 MHz NMR spectrophotometer (chemical shifts in δ ppm) using TMS as an internal standard. The mass spectra were recorded on Shimadzu 2010A LCMS spectrophotometer (m/z and relative intensity). All the reactions were routinely monitored and purity of the compounds was ascertained by thin layer Chem Sci Trans., 2013, 2(3), 813-820 815 chromatography on aluminium plates precoated with silica gel G (Merck silica gel 60 F 254 ) in various solvent systems of different polarity. All the chemicals (Sigma Aldrich, Acrose, Hi-media) and solvents (Qualigens) used were of AR grade and solvents were purified by suitable methods. Diclofenac sodium and aceclofenac were obtained from Karnataka Antibiotics & Pharmaceuticals Ltd., (KAPL) Bangalore as a gift samples. Aceclofenac impurities were prepared by following procedure 
Synthesis of impurity -A: [2-[(2, 6-dichlorophenyl)amino]phenyl]acetic acid
5 g of Sodium 2-[2-(2,6-dichloroanilino)phenyl]acetate (diclofenac sodium) was taken in a 250 mL round bottom flask, 50 mL of 10% hydrochloric acid was added. The mixture was refluxed for 2 h in order to complete the hydrolysis of sodium salt. The reaction mixture was neutralized with dilute sodium carbonate solution. The mixture was filtered to get white solid and dried. The solid was recrystallized with methanol and water mixture 
Synthesis of impurity -C: Ethyl [2-[(2, 6-dichlorophenyl) amino]phenyl]acetate
To a solution of 5 g of [2-[(2,6-dichlorophenyl)amino]phenylacetic acid (0.0169 mol) in 80 mL of anhydrous N,N-dimethylformamide, 2.58 g of anhydrous potassium carbonate (0.0186 mol) and then 3.3 mL of diethyl sulfate 12 (0.02535 mol) were added at room temperature. The reaction mixture was stirred for 12 h. The reaction mixture was filtered and washed with N,N-dimethylformamide. The combined filtrate was poured slowly into ice cooled water with continuous stirring to give white precipitate. The mixture was filtered and precipitate thoroughly washed with cooled water. The dry product was recrystallized from petroleum ether to give ethyl [2-[(2, 6-dichlorophenyl) amino] phenylacetate 13 (Impurity-C). 
Synthesis of impurity -D: Methyl [[[2-[(2,6-ichlorophenyl)amino]phenyl]acetyl]oxy] acetate

Synthesis of impurity -E: Ethyl [[[2-[(2,6-dichlorophenyl) amino]phenyl]acetyl]oxy] acetate
Synthesis of impurity-F: Benzyl [[[2-[(2,6-dichlorophenyl) amino]phenyl]acetyl]oxy] acetate
817 benzyl bromoacetate were added drop wise. The resulting mixture was stirred under 50 0 C for 12 h. Then, the reaction solvent was removed under reduced pressure and sodium salts were precipitated by adding 400 mL of ethyl ether. The ether phase was then filtered and washed three times with 10 mL of water and then dried on sodium sulphate. The ether phase was then concentrated until an oil was obtained, and was washed twice with 20 mL of hexane. The resulting product was isolated by column chromtography using silica gel and petroleum ether: ethyl acetate (10:1) to give benzyl 2-[(2,6-dichlorophenyl)amino] phenylacetoxy acetate 14 in the form of white crystals.
Synthesis of impurity-I: 1-(2, 6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one
3 g of {2-[(2,6-Dichlorophenyl)amino]phenyl}acetic acid(impurity-A) in a 250 mL beaker and 50 mL of 25% sulfuric acid was added. The mixture was irradiated in micro-wave oven at 490 watts for 10 min. The reaction mixture was allowed to cool and reaction mixture was neutralized with 10% sodium carbonate solution. Then resultant solution was extracted with chloroform (4x10 mL). The chloroform extracts were combined and concentrated the organic solution gave 1-(2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one. The dried product was chromatographed in silica gel column using cyclohexane and ethyl acetate (3:1) gave pure 1-(2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one 15-17 (Impurity -I). 
Results and Discussion
Physical data of synthesized aceclofenac impurities are presented in Table 1 . Process related impurities of aceclofenac have been synthesized and the structure of synthesized impurities characterized by FT-IR, MS and 1 H NMR spectral data. Impurity-A was synthesized by simple and direct acid hydrolysis. (aceclofenac) . Hence considerable modification was adopted to synthesize these impurities. Impurity B,C,D and E were synthesized by simple methylation and ethylation of
